30 Oct 2017 --- Researchers have found evidence of the inhibitory effect in colon tumorigenesis of a low dose combination of aspirin and Sabinsa’s Curcumin C3 Complex. The findings have been published in the journal Biochemical Pharmacology.
Colorectal cancer (CRC) is one of the major causes of human mortality and morbidity. Colitis-accelerated colon cancer (CAC) is a sub-type of CRC that is also closely associated with inflammatory bowel disease (IBD). Although aspirin has been widely investigated as a chemopreventive agent for CAC and different types of CRC, the potential side-effect of gastrointestinal bleeding has been a concern in long-term high-dose aspirin therapy.
In this new study on animals, researchers at Rutgers discovered that co-administration of Curcumin C3 Complex and aspirin helps to lower the dose of aspirin by 50 percent rendering this therapy feasible without adverse effects. It has been known earlier that Curcumin C3 complex is non-toxic at all tested doses.
Additionally, aspirin and C3 Complex combination modulated larger gene sets than the single agent treatment. These genes were involved in several canonical pathways important in the inflammatory network and liver metastasis in CAC. Also, this was the first study is first of its kind in an Azoxymethane(AOM)/DSS (Dextran sulfate sodium)-induced CAC.
“Extensive research on Curcumin C3 Complex continues to reveal additional applications and benefits, which fosters further studies added to the large body of science on C3 Complex,” says Sabinsa founder Dr. Muhammed Majeed. “The range of health benefits scientific investigation has identified continues to inspire researchers across the globe.”
At Vitafoods Asia 2017, NutritionInsight spoke with Sabinsa CEO Shaheen Majeed about curcumin and other trending nutritionals. Curcumin, one of the natural compounds present in the turmeric rhizomes has been a focus of clinical investigations for management of several life style diseases or conditions such as Alzheimer, arthritis, liver disorders, hangovers, inflammation, hypercholesterolemia and asthma. With increasing research into biological functions and activities of curcumin, another area of curcumin biology is gaining a lot of attention – its metabolites.
Earlier this month, Sabinsa’s parent company Sami Labs inaugurated a second Continuous Extraction Plant to meet the demand for Curcumin C3 Complex. This new facility will be exclusively used for curcumin extraction, increasing production of Curcumin C3 Complex to 25 tons from the previous capacity of 6 tons. The two Continuous Extraction units are spread across 5 acres in Dobaspet, Bangalore, India.
09 Apr 2018 –
Novartis has entered into an agreement and plan ...
23 Mar 2018 –
Probi has signed a long-term agreement with ...
12 Mar 2018 –
Gelita is offering manufacturers of soft gelatin ...
02 Mar 2018 –
The commissioner of the US Food and Drug ...
02 Mar 2018 –
A new study has observed a link between certain ...